amgen glp 1 agonist A Booming Weight-Loss Drug Discovery Landscape at a Glance GLP-1s & Beyond: Understanding Incretin
Description
Diabetologia 56, 14131416
10.1016/j.molmet.2023.101850 55 MosserD
The body weight loss observed in this study opens perspectives for a pharmacological treatment of obesity as an alternative to various procedures of bariatric surgery
10.1111/dom.12802 Summary Keywords type 2 diabetes, DPP-4 inhibitors, oral antidiabetic, incretin-based therapy, gliptin, combination therapy Citation Gallwitz B (2019) Clinical Use of DPP-4 Inhibitors
Mosenzon O, Rosenlund S, Eriksson JW, et al
Multiply 0.35 ml by 20mg/ml
